Opioid Use Disorder Clinical Trials in New York, New York

12 studies are recruiting for opioid use disorder in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Brenipatide in Participants With Opioid Use Disorder

   The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 14…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Adams Clinical Harlem, New York, New York

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07420283 on ClinicalTrials.gov

2. GLP-1R Agonist Treatment for Opioid Use Disorder

   The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   NYU Langone Health, New York, New York

   Locations

   4 in total

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06548490 on ClinicalTrials.gov

3. Project I Test: Implementing HIV Testing in Opioid Treatment Programs

   This study will test two active evidence-based "practice coaching" (PC) interventions to improve opioid treatment programs' (OTPs') provision and sustained implementation of on-site 1) HIV testing and linkage to care and 2) HIV/Hepatitis C virus (HCV) testing and linkage to care among patients seek…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT03135886 on ClinicalTrials.gov

4. Assessing Optimal XRB Initiation Points in Jail

   This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be induct…

   Stage

   Phase 4

   Ages

   Any age

   Site

   NYU Langone Health - 180 Madison Ave, New York, New York

   Locations

   4 in total

   Run by

   NYU Langone Health

   See if you can join NCT06051890 on ClinicalTrials.gov

5. Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

   The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) and/or other Substance Use Disorders (SUDs) by assessing its safety and tolerability in s…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   4 in total

   Run by

   InSightec

   See if you can join NCT04197921 on ClinicalTrials.gov

6. Smartphones for Opiate Addiction Recovery

   Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates th…

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   NYU Langone, New York, New York

   Locations

   2 in total

   Run by

   NYU Langone Health

   See if you can join NCT05033028 on ClinicalTrials.gov

7. A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

   The goal of this clinical trial is to compare buprenorphine formulations (sublingual buprenorphine versus long-acting injectable buprenorphine) for treating opioid use disorder among individuals who use fentanyl and/or other high potency synthetic opioids. Individuals aged 18-65 will be eligible fo…

   Stage

   EARLY_Phase 1

   Ages

   18 to 65

   Site

   Substance Treatment and Research Service, New York, New York

   Run by

   Rachel R. Luba

   See if you can join NCT06726200 on ClinicalTrials.gov

8. Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform

   The study aims to adapt an existing Cultural Structural Humility (CSH) training into a video format for peer recovery coaches (PRCs) and refine an AI-driven texting tool to reinforce the training. After refining these tools using user-centered design, a pilot test will be conducted to assess their …

   Stage

   Not phased

   Ages

   18 to 99

   Site

   START Treatment and Recovery, New York, New York

   Run by

   Friends Research Institute, Inc.

   See if you can join NCT06573476 on ClinicalTrials.gov

9. Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

   This study will evaluate the effectiveness of a new pharmacological approach to increase efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with opioid use disorder by combining it with buprenorphine-naloxone. This is a two arm, double-blind, placebo-controlled s…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Stars/Nyspi, New York, New York

   Locations

   2 in total

   Run by

   New York State Psychiatric Institute

   See if you can join NCT05011266 on ClinicalTrials.gov

10. Clinical Trials of Multivalent Opioid Vaccine Components

    Currently, abuse of prescription opioid analgesics and heroin is a serious problem in the U.S. Although several medications, including methadone, buprenorphine, and naltrexone, are available and effective in treating opioid use disorder (OUD), long-term relapse rates remain high. The current study …

    Stage

    Phase 1

    Ages

    18 to 59

    Site

    New York State Psychiatric Institute: Division on Substance Use Disorders, New York, New York

    Locations

    2 in total

    Run by

    New York State Psychiatric Institute

    See if you can join NCT04458545 on ClinicalTrials.gov

11. E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

    The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking…

    Stage

    Phase 2

    Ages

    21 to 75

    Site

    NYU Langone Health, New York, New York

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05722561 on ClinicalTrials.gov

12. Psilocybin for Opioid Use Disorder (OUD)

    This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who continue to use illicit opioids in spite of adherence to standard-of-ca…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    NYU Langone Health, New York, New York

    Locations

    5 in total

    Run by

    NYU Langone Health

    See if you can join NCT06796062 on ClinicalTrials.gov